[go: up one dir, main page]

SV2003001054A - Derivados de pirroles nuevos como agentes farmaceuticos ref. x-15017 - Google Patents

Derivados de pirroles nuevos como agentes farmaceuticos ref. x-15017

Info

Publication number
SV2003001054A
SV2003001054A SV2002001054A SV2002001054A SV2003001054A SV 2003001054 A SV2003001054 A SV 2003001054A SV 2002001054 A SV2002001054 A SV 2002001054A SV 2002001054 A SV2002001054 A SV 2002001054A SV 2003001054 A SV2003001054 A SV 2003001054A
Authority
SV
El Salvador
Prior art keywords
rent
optionally replaced
hydrogen
ring
members
Prior art date
Application number
SV2002001054A
Other languages
English (en)
Inventor
Jason Scott Sawyer
Douglas Wade Beight
Paola Ciapetti
Todd Vincent Decollo
Alexander Glenn Godfrey
Jr Theodore Goodson
David Kent Herron
Hong-Yu Li
Viktor Junkai Liao
William Thomas Mcmillen
Shawn Christopher Miller
Nicholas Anthony Mort
Edward C R Smith
Jonathan Michael Yingling
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of SV2003001054A publication Critical patent/SV2003001054A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

ESTE INVENTO SE REFEIERE A UN COMPUESTO DE LA ESTRUCTURA, VER ESTRUCTURA, EN DONDE X ES UN ANILLO DE CUATRO, CINCO O SEIS MIEMBROS Y X ES C, O O S;R1 ES FENILO, O FENILO OPCIONALMENTE SUSTITUIDO; PIRIDINO, O PIRIDINIO OPCIONALMENTE SUSTITUIDO; N-OXIDO PIRIDINO, O N-OXIDO PIRIDINO OPCIONALMENTE SUSTITUIDO; QUINOLINA, O QUINOLINA OPCIONALMENTES SUSTITUIDA; N-OXIDO DE QUINOLNA, O OPCIONALMENTE SUSTITUIDA; N-OXIDO DE QUINOLINA OPCIONALMENTE SUSTITUIDA; NAFTIRIDINA; PIRAZONA; O TIOFENO; EN DODNE LA SUSTITUCION PUEDE SER UNO O MAS DE LOS SIGUIENTES:HIDROGENO (C1-C6)ALQUILO, (C2-C6)ALQUENILO, (C2-C6)ALQUINILO(C1-C6)ALCOXI (C2-C6)ALQUENILOXI(C2-C6)ALQUINILOXI(C1-C6)ALQUILTIO, (c1-C6)ALQUILSULFINILO(C1-C6)ALQUILSULFONILO(C1-C6)ALQUILAMINO, DI-[(C1-C6)ALQUILO]AMINO, (C1-C6)ALCOXICARBONILO, N-(c1-C6)ALQUILCARBONILO, N-(C1-C6)ALQUILCARBOILO, N,N-DI-[(C1-C6)ALQUILO]CARBAMOILO, (C2-C6)ALCANOILO, (C2-C6)ALCANOILO, (C2-C6)ALCANOILOXI(C2-C6)ALCANOILAMINO, N-(C1-C6)ALQUIL(C2-C6)ALCANOILAMINO, (C3-C6)ALQUENOILAMINO, N-(C1-C6)ALQUIL-(C3-C6)ALQUENOILAMINO, (C3-C6)ALQUINOILAMINO, N-(c1-C6)ALQUIL-(C3-C6)ALQUINOILAMINO, N-(C1-C6)ALQUILSULFAMOILO, N,N-DI-[(C1-C6)ALQUILO]SULFAMOILO, (C1-C6)ALCANOSULFONILAMINO, N-(c1-C6)ALQUILO-(C1-C6)ALCANOSULFONILAMINO, CARBOXAMIDA, ETILENO, TIOFENILO, AMINOFENILO, TRIFLUOROFENILO, HALO, TRIFLUOROMETOXI, HIDROXIEMTILO, N-PIRROLIDINILO, N-MOROFOLINO, FENILTIO, DIALQUILAMINOMETILO, EMTOXIFENILO, AMINO, HIDROXI, CARBOXILO, FENILO, ARILALQUILO; R2 ES QUINOLINA OPCIONALMENTE SUSTITUIDA; N-OXIDO DE QUINOLINA, O N-OXIDO DE QUINOLINA OPCIONALMENTE SUSTITUIDA; FENILO, O FENILO OPCIONALMENTE SUSTITUIDO; NAFTALENO, O NAFTALENO OPCIONALMENTE SUSTITUIDO; PIRIDINA O PIRIDINA OPCIONALMENTE SUSTITUIDA; N-OXIDO DE PIRIDINA, O N-OXIDO DE PIRIDINA OPCIONALMENTE SUSTITUIDA; QUINAZOLINA, O QUINAZOLINA OPCIONALMENTE SUSTITUIDA; CINOLINA CINOLINA OPCIONALMENTE SUSTITUIDA; BENZODIOXOL, O BENZODIOXOL OPCIONALMENTE SUSTITUIDO; BENZODIOXANO, O BENZODIOXANO OPCIONALMENTE SUSTITUIDO; PIRIMIDINA, O PIRIMIDINA OPCIONALMENTE SUSTITUIDA; BENZOTIOFENO, O BENZOTIOFENO OPCIONALMENTE SUSTITUIDO; O FENANTROLENO, EN DONDE LA SUSTITUCION PUEDE SER, INDEPENDEINTEMENTE UNA O MAS DE LAS SIGUIENTES; HIDROGENO, (C1-C6)ALQUILO, (C2-C6)ALQUENILO, (C2-C6)ALQUINILO, (C1-C6)ALQUILHALURO, (C1-C6)ALCOXI(C2-C6)ALQUENILOXI(C2-C6)-ALQUINILOXI(C1-C6)ALQUILTIO, (C1-C6)ALQUILSULFONILO(C1-C6)ALQUILSULFONILO, (c1-C6)ALQUILAMINO, DI-[(C1-C6)ALQUILO]AMINO, (C1-C6)ALCOXICARBONILO, N-(C1-C6)ALQUILO]CARBAMOILO, AMINOOXI, N-(C1-C6)ALQUILO, AMINOOXI, N,N-DI-[(C1-C6)ALQUILO]AMINOOXI, (c2-C6)ALCANOILO, (c2-C6)ALCANOILOXI, (C2-C)ALCANOILAMINO, N-(C1-C6)ALQUKL-(C2-C6)ALCANOILAMINO, (c3-C6)ALQUENOILAMINO, N-(C1-C6)ALQUIL-(C3-C6)ALQUENOILAMINO, (C3-C6)ALQUINOILAMINO, N-(C1-C6)ALQUIL(C3-C6)ALQUINOILAMINO, SULFAMOILO, N-(C1-6C)ALQUILSULFAMOILKO, N,N-DI-[(C1-C6)ALQULO]SULFAMOILO, (c1-C6)ALCANOSULFONILAMINO, N-(C1-C6)ALQUIL-(c1-C6)ALCANOSULFONILAMIONO, CARBOXAMIDA, ETILENIO, TIOFENILO, AMINOFENILO, FENILTIO, HALO, CIANO, PIRIDINILO, HIDROXI, N-PIRROLIDINO, N-MORFOLINO, CARBOXILO, [5-FENILO-1,2,4-OXADIAZOL-3-ILO]METOXI, (5-OXO-PIRROLIDINO)METOXI, 2-(4,5-DIHIDRO-1H-IMIDAZOLILO),N,N-DIALQUILCARBAMOILOXI, 1-HDIROXI-1-METILETILO, 4-FLUOROFENILO, 3,4-METILENDIOXIFENILO, TRIFLUOROMETILO, TRIFLUOROMETOXI, VER FORMULAS EN DODNE: X1 ES O,N,S, SO2NR13, C(O), O ENLACE; Q1 ES HIDROGENO, FENILO, 5-(2,2-DIFLUORO-1,3-BENZODIOXOLILO), C(O)Q5, O PIRIDILO CUADNO M Y N SON INDEPENDIENTEMENTE 0-2; Q1 ES OR11NR11NR11R12, HALO, N-MORFOLINO, N-PIPERAZINO-N'TRIAZOLILO, N-(4-PIPERIDINILPIPERIDINA), SO2R14, SOR14, NHSO2R15, ACETAMIDO, N-FTALIMIDO, N-OXADIAZOLIDINO, N-BENZOXAZOLIDINO, N-PIRROLIDINILO, N(N'-METILBENCIMIDAZOLINO, N,N-(C1-C4)ALCOXI,N-BENZIMIDAZOLINO; CUANDO M Y N SON INDEPENDIENTEMENTE 0-2, PERO UNA DE LAS DOS YA SE AM O N NO ES 0, Q5 E SHDIROXI, METOXI, AMINO, DIETILAMINO, DIEMTILAMINO, R10 ES HIDROGENO, HALO, (C1-C6)ALQUILO; R11 Y R12 SON INDEPENDIENTEMENTE HIDROGENO, (c1-C6)ALQUILO, (C1-C6)ALCOXI, ARILALQUILO, CICLOALQUILO, CICLOALQUILMETILO, 4-(N-METILPIPERIDINO, PIRIDILO, O R11 Y R10 SE PUEDEN UNIR PARA FORMAR UN ANILLO DE 4,5,6 O 7 MIEMBROS, O R11 Y R12 SE PUEDEN JUNTAR PARA FORMAR UN ANILLO DE 3,4,5,6 O 7 MIEMBROS; R13 ES HIDROGENO, (C1-C6)ALQUILO, 2-METOXIFENILO, R14 E S2-PIRIDIMIDINILO, N-METIL-2-IMIDAZOLILO, 4-CLOROFENILO, 2-PIRIDILMETILO; R15 ES (C1-C6)ALQUILO, N-METIL-4-IMIDAZOLIL; R16 ES HIDROGENO, HALO, ALQUILO, ARILO, VER FORMULA, EN DONDE; Q2 ES HIDROGENO, 4-IMIDAZOLILO, O C(O)NR24R25 CUANDO O Y P SON INDEPENDIENTEMENTE 0-2; Q2 ES OR23, NR24R25, O N-MORFOLINO, CUANDO O Y P SON INDEPENDIENTEMENTE 0-2 PERO UNA DE ELLAS YA SEA O O P NO SEA 0; R20 ES HIDROGENO, O (C1-C6)ALQUILO; R21 ES HIDROGENO, (C1-C6)ALQUILO, O R21 Y R20 SE PUEDEN JUNTAR PARA FORMAR UN ANILLO DE 4,5,6 O 7 MIEMBROS; R22 ES HIDROGENO, (C1-C6)ALQUILO, ARIALQUILO, ARILO, O R21 Y R22 PUEDEN UNIRSE PARA FORMAR UN ANILLO DE 4,5,6,7 MIEMBROS; R23 ES HIDROGENO O (c1-C6)ALQUILO; R24 ES HIDROGENO, (C1-C6)ALQUILO, O R24 Y R25 PUEDEN TOMARSE JUNTAS PARA FORMAR UN ANILLO DE 3,4,5,6, O 7 MIEMBROS, O R24 Y R20PUEDEN TOMARSE JUTNAS PARA FORMAR UN ANILLO DE 6 O 7 MIEMBROS; R25 ES HIDROGNEO (C1-C6) ALQUILO O ACETILO, O UN GRUPO DE FORMULA VER FORMULA, EN DONDE R30 ES HIDROGENO, O (C1-C6)ALQUILO, R31 ES HIDROGENO, (C1-C6)ALQUILO, 2-PIRIDILO, PIRIDILMETILO, AMINO O HIDROXI, O UN GRUPO DE FORMULA VER FORMULA, EN DONDE R32 Y R33 SON CADA UNA INDEPENDIENTEMENTE HIDROGENO, (C1-C6)ALQUILO,A CETILO, ALQUILSULFONILO, O R32 Y R33 SE PUEDEN JUNTAR PARA FORMAR UN ANILLO DE 4,5,6 O 7 MIEM,BROS, VER FORMULA, EN DONDE X2 ES CH2, O, O N; Q ES 2-*3 EXCEPTO QUE Q3 ES UN ENLÑACE, Q ES 0-3; Q3 ES NR36R37, OR38, O UN ENLACE; R35 ES HDIROGENO, O R35 Y Q3 ES UN ENLACE Q3 ES UN ENLACE Q ES 0-3; Q3 ES NR36R37, OR38, O UN ENLACE; R35 ES HIDROGENO, O R35 Y Q3(CUANDO Q3 ES UN ENLACE PUEDEN JUNTARSE PARA FORMAR UN ANILLO DE 5 MIEMBROS; R36, R37 Y R3 CADA UNA SON INDEPENDIENTEMENTE HIDROGENO, O (C1-C6)ALQUILO, O UN GRUPO DE FORMULA, EVR FORMULA, EN DONDE X3 ES CIANO, CARBOXAMIDA, N,N-DIEMTILCARBOXAMIDA, N,N-DIEMTILCARBOXAMIDA, N,N-DIEMTILAMINOMETILO, 4-MERILPIPERAZIN-1ILO-EMTILO O CARBOXILATO, O UN GRUPO DE FORMULA EN DONDE Q6 ES NR41R42; R ES 2-3; R40 E SHDIROGENO, O (C1-C6)=ALQUILO; R41 Y R42 SON HIDROGENO, (C1-C6)ALQUILO, O R41 Y R40 PUEDEN TOMARSE JUNTAS PARA FORMAR UN ANILLO DE 6 O 7 MIEMBROS, UN GRUPO DE FORMULA. VER FORMUAL EN DONDE: Q7 ES HIDROXI, METOXI, O N-PIPERIDINILO; CON LA CONDICION DE QUE R1 Y R2 NO PUEDEN SER AMBAS FENILO O FENILO OPCIONALMENTE SUSTITUIDO, Y CON LA CONDICION DE QUE CUANDO YA SEA R1 O R2 SENA FENILO O FENILO OPCIONALMENTE SUSTITUIDO, LA OTRA NO PUEDEN SER TIOFEN-2-ILO Y SIEMOPRE Y CUADNO R2 SEA QUINOLINA-4-ILO, SUSTITUCION EN LA POSICION 7 DE QUINOLINA NO PUEDEN INCLUIR ARILO, HETEROARILO, ARILO FUSIONADO, NI HETEROARILO FUSIONADO.K ES 1-8; R3 UNA O MAS DE LAS SIGUIENTES: HDIROGENO; (C1-C4)ALQUILO; (C1-C4)ALQUILHIDORXI; HIDROXI; HIDROXI; N,N-DI(C1-C4)ALQUILAMINO(C1-C4)ALCOXI; OXIEMTILO DE BENCILo; FENILOXIMETILO, OXO, CARBOXILO(C1-C4)ALQUILARILO; BENCILOXI, ACETOXI, AMINO(C1-C4)ALQUILO; (C1-C4)ALQUENILO; HALO; -O-(C1-C4)CLOROFENILO; ACETONITRILO; FENILO, O UN FENILO OPCIONALMENTE SUSTITUIDO; EN DONDE LA SUSTITUCION PUEDE SER UNO O MAS DE LO SIGUIENTE:(C1-C6) ALCOXI, HALO, CARBOXI, O (C1-C6)ALCOXICARBONILO; Y LAS SALES FARMACEUTICAMENTE ACEPTABLES, ESTERES Y PRODROGAS DE ELLOS.
SV2002001054A 2001-05-24 2002-05-24 Derivados de pirroles nuevos como agentes farmaceuticos ref. x-15017 SV2003001054A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29346401P 2001-05-24 2001-05-24

Publications (1)

Publication Number Publication Date
SV2003001054A true SV2003001054A (es) 2003-03-18

Family

ID=23129192

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2002001054A SV2003001054A (es) 2001-05-24 2002-05-24 Derivados de pirroles nuevos como agentes farmaceuticos ref. x-15017

Country Status (37)

Country Link
US (1) US7087626B2 (es)
EP (1) EP1397364B1 (es)
JP (2) JP4519407B2 (es)
KR (1) KR100861630B1 (es)
CN (2) CN1951939A (es)
AR (1) AR036034A1 (es)
AT (1) ATE368041T1 (es)
AU (1) AU2002339268B2 (es)
BR (1) BR0209939A (es)
CA (1) CA2446820C (es)
CO (1) CO5540282A2 (es)
CY (1) CY1106871T1 (es)
CZ (1) CZ303808B6 (es)
DE (1) DE60221392T2 (es)
DK (1) DK1397364T3 (es)
DZ (1) DZ3506A1 (es)
EA (1) EA007782B1 (es)
EC (1) ECSP034859A (es)
EG (1) EG25614A (es)
ES (1) ES2289116T3 (es)
HR (1) HRP20030961B1 (es)
HU (1) HU228844B1 (es)
IL (2) IL158512A0 (es)
MX (1) MXPA03010630A (es)
MY (1) MY134586A (es)
NO (1) NO326701B1 (es)
NZ (1) NZ528525A (es)
PE (1) PE20030117A1 (es)
PL (1) PL221339B1 (es)
PT (1) PT1397364E (es)
SI (1) SI1397364T1 (es)
SK (1) SK287857B6 (es)
SV (1) SV2003001054A (es)
TW (1) TWI329644B (es)
UA (1) UA76461C2 (es)
WO (1) WO2002094833A1 (es)
ZA (1) ZA200308546B (es)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ303808B6 (cs) * 2001-05-24 2013-05-09 Eli Lilly And Company Nové pyrazolové deriváty jako farmaceutická cinidla
US7199120B2 (en) * 2001-12-11 2007-04-03 Smithkline Beecham Corporation Pyrazolo-pyridine derivatives as antiherpes agents
EP1543001B1 (en) * 2002-09-17 2007-08-15 Eli Lilly And Company Pyrazolopyridine derivatives as tgf beta signal transduction inhibitors for the treatment of cancer
CA2506799A1 (en) * 2002-11-21 2004-06-10 Eli Lilly And Company Mixed lineage kinase modulators
UA80571C2 (en) * 2002-11-22 2007-10-10 Lilly Co Eli Quinolinyl-pyrrolopyrazoles
EP1578749A2 (en) * 2002-11-22 2005-09-28 Eli Lilly And Company Pyrazoloazepine compounds as pharmaceutical agents
US7405299B2 (en) * 2002-11-27 2008-07-29 Eli Lilly And Company Compounds as pharmaceutical agents
CL2004000234A1 (es) * 2003-02-12 2005-04-15 Biogen Idec Inc Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid
US7511065B2 (en) * 2003-11-12 2009-03-31 Eli Lilly And Company Mixed lineage kinase modulators
WO2005092894A1 (en) * 2004-03-01 2005-10-06 Eli Lilly And Company Fused pyrazole derivatives as tgf-beta signal transduction inhibitors for the treatment of fibrosis and neoplasms
TW200639163A (en) * 2005-02-04 2006-11-16 Genentech Inc RAF inhibitor compounds and methods
CA2603345C (en) 2005-04-01 2017-05-02 Insa Rouen New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-alzheimer agents
SI1910370T1 (sl) 2005-07-22 2015-06-30 Eli Lilly And Company Piridin kinolin substituirani pirolo(1,2-b)pirazol monohidrat kot tgf-beta inhibitor
JP5178515B2 (ja) * 2005-08-12 2013-04-10 シンタ ファーマシューティカルズ コーポレーション Ｈｓｐ９０活性を調節するピラゾール化合物
WO2007076127A2 (en) * 2005-12-22 2007-07-05 Biogen Idec Ma Inc Condensed imidazoles or pyrazoles and their use as transforming growth factor modulators
DE102005061840A1 (de) * 2005-12-23 2007-06-28 Merck Patent Gmbh Triazolderivate
EP2034995A2 (en) 2006-05-25 2009-03-18 Synta Pharmaceuticals Corporation Method for treating proliferative disorders associated with protooncogene products
HUE035575T2 (en) 2006-10-03 2018-05-28 Genzyme Corp Use of TGF-beta antagonists to treat children at risk of developing bronchopulmonary dysplasia
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
WO2009076440A2 (en) * 2007-12-12 2009-06-18 E.I. Du Pont De Nemours And Company Fungicidal bicyclic pyrazoles
WO2010070060A1 (en) * 2008-12-19 2010-06-24 Nerviano Medical Sciences S.R.L. Bicyclic pyrazoles as protein kinase inhibitors
US20100267731A1 (en) * 2009-04-17 2010-10-21 Summa Health Systems, LLC Use of transforming growth factor-b receptor inhibitors to suppress ocular scarring
AR081810A1 (es) * 2010-04-07 2012-10-24 Bayer Cropscience Ag Piridinilpirazoles biciclicos
US9205086B2 (en) 2010-04-19 2015-12-08 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a Hsp90 inhibitory compounds and a EGFR inhibitor
EP2401915A1 (en) 2010-06-29 2012-01-04 Basf Se Pyrazolopyridine compounds
EP2402337A1 (en) * 2010-06-29 2012-01-04 Basf Se Pyrazolopyridine compounds
EP2402338A1 (en) 2010-06-29 2012-01-04 Basf Se Pyrazolopyridine compounds
EP2402340A1 (en) 2010-06-29 2012-01-04 Basf Se Pyrazolopyridine compounds
EP2402339A1 (en) * 2010-06-29 2012-01-04 Basf Se Pyrazolopyridine compounds
US8871744B2 (en) 2010-07-21 2014-10-28 B & G Partyers, LLC Compounds and methods for selectively targeting tumor-associated mucins
WO2012138945A1 (en) 2011-04-08 2012-10-11 Aestus Therapeutics, Inc. Methods of treating schizophrenia with pyrazole derivative inhibitors of tgf - beta
EP2737083A1 (en) 2011-07-27 2014-06-04 INSERM (Institut National de la Santé et de la Recherche Scientifique) Methods for diagnosing and treating myhre syndrome
BR112014009789A2 (pt) 2011-10-26 2017-04-25 Seattle Children's Res Inst cisteamina no tratamento da doença fibrótica
JP2014534228A (ja) 2011-11-02 2014-12-18 シンタ ファーマシューティカルズ コーポレーション 白金含有剤とｈｓｐ９０阻害剤の組合せ療法
EP2773345A1 (en) 2011-11-02 2014-09-10 Synta Pharmaceuticals Corp. Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors
CA2854188A1 (en) 2011-11-14 2013-05-23 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitors with braf inhibitors
US9782452B2 (en) 2011-11-22 2017-10-10 Cornell University Methods for stimulating hematopoietic recovery by inhibiting TGFβ signaling
EA032679B1 (ru) 2012-10-05 2019-07-31 Кадмон Корпорейшн, Ллк Человеческие анти-vegfr-2/kdr-антитела
TWI443096B (zh) 2012-12-18 2014-07-01 Ind Tech Res Inst ３－（５－（４－（３－氟丙基）哌嗪－１－基）苯並咪唑－２－基）－１－氮雜薁－２－酮之單水合晶型及其製備方法與藥學組成物
JP2016507537A (ja) * 2013-02-07 2016-03-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 置換アセチレン誘導体およびｍＧｌｕＲ４の正のアロステリックモジュレーターとしてのそれらの使用
RS60371B1 (sr) 2013-03-14 2020-07-31 Brigham & Womens Hospital Inc Sastavi i postupci za ekspanziju i kultivisanje epitelnih matičnih ćelija
US8975417B2 (en) * 2013-05-27 2015-03-10 Novartis Ag Pyrazolopyrrolidine derivatives and their use in the treatment of disease
JP6466461B2 (ja) 2014-02-03 2019-02-06 ヴァイティー ファーマシューティカルズ，インコーポレイテッド Ｒｏｒガンマのジヒドロピロロピリジン阻害剤
CA2959404A1 (en) 2014-09-03 2016-03-10 The Brigham And Women's Hospital, Inc. Compositions, systems, and methods for generating inner ear hair cells for treatment of hearing loss
TWI582083B (zh) 2014-10-07 2017-05-11 美國禮來大藥廠 胺基吡啶基氧基吡唑化合物
US9663515B2 (en) 2014-11-05 2017-05-30 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
EP3277673B1 (en) 2015-04-01 2022-05-04 Rigel Pharmaceuticals, Inc. Tgf-beta inhibitors
EP3313420B1 (en) 2015-06-25 2024-03-13 The Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance
ES2856931T3 (es) 2015-08-05 2021-09-28 Vitae Pharmaceuticals Llc Moduladores de ROR-gamma
BR112018010018A2 (pt) * 2015-11-20 2018-11-21 Vitae Pharmaceuticals Inc moduladores de ror-gama
JP2019506153A (ja) 2016-01-08 2019-03-07 マサチューセッツ インスティテュート オブ テクノロジー 分化した腸内分泌細胞およびインスリン産生細胞の作製
TWI757266B (zh) 2016-01-29 2022-03-11 美商維它藥物有限責任公司 ＲＯＲ－γ調節劑
US11260130B2 (en) 2016-03-02 2022-03-01 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV
US10201540B2 (en) 2016-03-02 2019-02-12 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
US10213511B2 (en) 2016-03-02 2019-02-26 Frequency Therapeutics, Inc. Thermoreversible compositions for administration of therapeutic agents
US20190119642A1 (en) 2016-03-15 2019-04-25 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion
AU2017284124B2 (en) * 2016-06-13 2021-06-03 Genfleet Therapeutics (Shanghai) Inc. Benzotriazole-derived α and β unsaturated amide compound used as TGF-βR1 inhibitor
CN107663206B (zh) 2016-07-29 2021-06-18 上海璎黎药业有限公司 含氮芳香杂环化合物、其制备方法、药物组合物和应用
WO2018125746A1 (en) 2016-12-30 2018-07-05 Frequency Therapeutics, Inc. 1h-pyrrole-2,5-dione compounds and methods of using them to induce self-renewal of stem/progenitor supporting cells
WO2018204661A1 (en) * 2017-05-05 2018-11-08 Arcus Biosciences, Inc. Quinazoline-pyridine derivatives for the treatment of cancer-related disorders
MX2020000887A (es) 2017-07-24 2020-07-22 Vitae Pharmaceuticals Llc Inhibidores de ror?.
WO2019018975A1 (en) 2017-07-24 2019-01-31 Vitae Pharmaceuticals, Inc. INHIBITORS OF ROR GAMMA
RS63581B1 (sr) 2017-10-05 2022-10-31 Fulcrum Therapeutics Inc Inhibitori p38 kinaze smanjuju ekspresiju dux4 i nizvodnih gena u cilju lečenja fshd
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
JP7362600B2 (ja) 2017-10-11 2023-10-17 エフ． ホフマン－ラ ロシュ アーゲー Ｒｉｐ１キナーゼ阻害剤として使用するための二環式化合物
JP2021035911A (ja) * 2017-11-15 2021-03-04 大日本住友製薬株式会社 縮環ピラゾール誘導体及びその医薬用途
PT3725786T (pt) * 2017-12-13 2023-10-17 Genfleet Therapeutics Shanghai Inc Forma cristalina e forma salina de inibidor de tgf-bri e método de preparação das mesmas
CN110066277B (zh) 2018-01-24 2021-07-23 上海璎黎药业有限公司 芳香杂环取代烯烃化合物、其制备方法、药物组合物和应用
CN110066276B (zh) 2018-01-24 2020-09-18 上海璎黎药业有限公司 芳香杂环化合物、其中间体、制备方法、药物组合物和应用
CN112135613A (zh) 2018-03-20 2020-12-25 西奈山伊坎医学院 激酶抑制剂化合物和组合物及使用方法
US20210254006A1 (en) 2018-06-06 2021-08-19 Ideaya Biosciences, Inc. Methods of culturing and/or expanding stem cells and/or lineage committed progenitor cells using lactam compounds
CN112867724B (zh) * 2018-07-23 2024-06-04 熙源安健医药(北京)有限公司 二膦酸盐药物缀合物
CN113195707A (zh) 2018-08-17 2021-07-30 频率治疗公司 用于通过上调jag-1来生成毛细胞的组合物和方法
US11617745B2 (en) 2018-08-17 2023-04-04 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by downregulating FOXO
KR102126576B1 (ko) 2018-09-19 2020-06-24 주식회사 대웅제약 4-메톡시 피롤 유도체의 제조 방법
WO2020088526A1 (zh) * 2018-10-31 2020-05-07 南京明德新药研发有限公司 作为TGF-βR1激酶抑制剂的双环吡唑类化合物
JP7466128B2 (ja) * 2018-11-22 2024-04-12 フンダシオ インスティテュート デ レセルカ ビオメディカ（アイアールビー バルセロナ） ＴＧＦβ阻害剤およびプロドラッグ
IL284266B2 (en) 2018-12-27 2024-06-01 Nexys Therapeutics Inc History of (pyridin-2-yl)amine as an inhibitor of TGF-β in the cell R1 (ALK5) for cancer treatment
AU2019419414A1 (en) 2018-12-31 2023-04-06 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
US12325695B2 (en) 2019-01-24 2025-06-10 Jiangsu Aosaikang Pharmaceutical Co., Ltd. 5-(4-pyridyloxy)pyrazole compounds serving as TGF-βR1 kinase inhibitor
EP3917911A1 (en) 2019-01-31 2021-12-08 Kyorin Pharmaceutical Co., Ltd. 15-pgdh inhibitors
WO2020201362A2 (en) 2019-04-02 2020-10-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting and preventing cancer in patients having premalignant lesions
CN113557236B (zh) * 2019-06-10 2022-05-10 中国科学院广州生物医药与健康研究院 一种双功能免疫调节剂及其在药学上可接受的盐、药物组合物
CA3164037A1 (en) 2020-01-08 2021-07-15 Synthis Therapeutics, Inc. Alk5 inhibitor conjugates and uses thereof
WO2022017208A1 (zh) * 2020-07-23 2022-01-27 江苏奥赛康药业有限公司 作为TGF-βR1抑制剂的吡啶氧基连吡唑类化合物的盐型、晶型以及其药物组合物
WO2022063050A1 (zh) 2020-09-28 2022-03-31 四川科伦博泰生物医药股份有限公司 吡唑类化合物及其制备方法和用途
CN114437082B (zh) * 2020-11-06 2025-04-04 江苏先声药业有限公司 喹啉类化合物
CN115703750B (zh) * 2021-08-17 2024-07-02 黑龙江华瑞生物科技有限公司 一种1-氨基-4-甲基哌嗪的提取纯化方法
CN114249742B (zh) * 2021-11-22 2022-11-01 郑州大学 一种光气探针、荧光书写检测笔及其在光气检测中的应用
CN115969801B (zh) * 2023-03-21 2023-08-25 劲方医药科技(上海)有限公司 用于癌症的药物组合物及其制备方法
WO2024258967A1 (en) 2023-06-13 2024-12-19 Synthis Therapeutics, Inc. Anti-cd5 antibodies and their uses
GB202309553D0 (en) 2023-06-24 2023-08-09 Ucl Business Ltd Compostions and uses thereof
CN118652155A (zh) * 2024-06-17 2024-09-17 南京工业大学 一种二芳基乙炔的合成方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5356897A (en) * 1991-09-09 1994-10-18 Fujisawa Pharmaceutical Co., Ltd. 3-(heteroaryl)-pyrazololi[1,5-a]pyrimidines
DK0649425T3 (da) * 1992-06-17 1999-09-27 Upjohn Co Pyridino-, pyrrolidino- og azepino-substituerede oximer, som er anvendelige som anti-atherosklerose- og anti-hypercholester
GB9303993D0 (en) 1993-02-26 1993-04-14 Fujisawa Pharmaceutical Co New heterocyclic derivatives
ATE208199T1 (de) * 1993-07-27 2001-11-15 Kyowa Hakko Kogyo Kk Arzneimittel gegen parkinsonsche krankheit
US5358947A (en) * 1993-09-13 1994-10-25 American Cyanamid Company Angiotensin II receptor blocking 2,3-substituted pyrazolo[1,5-a]-1,3,5-triazin-4(3H)-ones
AUPN419395A0 (en) * 1995-07-17 1995-08-10 Treescope Development Co. Pty. Ltd. Plant protector
FR2746306B1 (fr) * 1996-03-22 1998-04-30 Oreal Compositions de teinture des fibres keratiniques contenant des pyrazolo-azoles ; leur utilisation pour la teinture comme coupleurs, procede de teinture
EA003925B1 (ru) 1997-05-22 2003-10-30 Дж.Д.Сирл Энд Ко ЗАМЕЩЕННЫЕ ПИРАЗОЛЫ, КАК ИНГИБИТОРЫ p 38 КИНАЗЫ
FR2772379B1 (fr) 1997-12-16 2000-02-11 Oreal Compositions de teinture des fibres keratiniques contenant des pyrazolo-azoles; leur utilisation pour la teinture comme base d'oxydation, procede de teinture; nouveaux pyrazolo-azoles
GB9809869D0 (en) 1998-05-09 1998-07-08 Medical Res Council Inhibition of protein kinases
EP1156045A4 (en) * 1999-01-28 2002-04-17 Nippon Shinyaku Co Ltd AMID DERIVATIVES AND DRUG COMPOSITIONS
JP2002541253A (ja) 1999-04-09 2002-12-03 スミスクライン・ビーチャム・コーポレイション トリアリールイミダゾール
DE60011100T2 (de) * 1999-08-27 2005-06-16 Abbott Laboratories, Abbott Park Als cox-hemmer verwendbare sulfonylphenylpyrazol-verbindungen
GB0007405D0 (en) 2000-03-27 2000-05-17 Smithkline Beecham Corp Compounds
PE20020506A1 (es) 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
CA2425288A1 (en) * 2000-10-11 2002-05-02 Sander G. Mills Pyrrolidine modulators of ccr5 chemokine receptor activity
ES2237671T3 (es) 2001-02-02 2005-08-01 Smithkline Beecham Corporation Derivados de pirazol contra la sobreexpresion de tgf.
CZ303808B6 (cs) * 2001-05-24 2013-05-09 Eli Lilly And Company Nové pyrazolové deriváty jako farmaceutická cinidla
PL1633912T3 (pl) * 2003-05-28 2014-11-28 Oerlikon Textile Gmbh & Co Kg Sposób oraz urządzenie do układania włókien wykorzystujące technikę igłowania powietrzem
JP4882198B2 (ja) 2003-09-25 2012-02-22 日産自動車株式会社 燃料電池システム

Also Published As

Publication number Publication date
HUP0400451A2 (hu) 2004-12-28
CN1269820C (zh) 2006-08-16
CA2446820C (en) 2010-07-13
JP2004535404A (ja) 2004-11-25
CZ20033128A3 (cs) 2004-06-16
AR036034A1 (es) 2004-08-04
TWI329644B (en) 2010-09-01
HUP0400451A3 (en) 2008-08-28
SI1397364T1 (sl) 2007-12-31
HRP20030961B1 (en) 2012-01-31
HRP20030961A2 (en) 2005-08-31
UA76461C2 (en) 2006-08-15
PT1397364E (pt) 2007-10-22
BR0209939A (pt) 2004-03-30
EA200301289A1 (ru) 2004-06-24
IL158512A0 (en) 2004-05-12
EP1397364A1 (en) 2004-03-17
HU228844B1 (en) 2013-06-28
US7087626B2 (en) 2006-08-08
SK287857B6 (sk) 2012-01-04
DE60221392T2 (de) 2008-04-17
CZ303808B6 (cs) 2013-05-09
SK14162003A3 (en) 2004-11-03
US20040106604A1 (en) 2004-06-03
DK1397364T3 (da) 2007-11-26
PL221339B1 (pl) 2016-03-31
KR100861630B1 (ko) 2008-10-07
IL158512A (en) 2009-07-20
ES2289116T3 (es) 2008-02-01
JP4519407B2 (ja) 2010-08-04
DE60221392D1 (de) 2007-09-06
CO5540282A2 (es) 2005-07-29
NO20035193D0 (no) 2003-11-21
EA007782B1 (ru) 2007-02-27
KR20030097895A (ko) 2003-12-31
WO2002094833A1 (en) 2002-11-28
NO20035193L (no) 2003-11-21
EP1397364B1 (en) 2007-07-25
MXPA03010630A (es) 2004-03-09
CN1951939A (zh) 2007-04-25
AU2002339268B2 (en) 2007-05-31
ATE368041T1 (de) 2007-08-15
HK1064375A1 (en) 2005-01-28
CY1106871T1 (el) 2012-09-26
ECSP034859A (es) 2004-01-28
PE20030117A1 (es) 2003-02-12
ZA200308546B (en) 2005-04-26
CN1511157A (zh) 2004-07-07
EG25614A (en) 2012-03-22
JP2009197016A (ja) 2009-09-03
NO326701B1 (no) 2009-02-02
PL367199A1 (en) 2005-02-21
MY134586A (en) 2007-12-31
NZ528525A (en) 2005-10-28
CA2446820A1 (en) 2002-11-28
DZ3506A1 (fr) 2002-11-28

Similar Documents

Publication Publication Date Title
SV2003001054A (es) Derivados de pirroles nuevos como agentes farmaceuticos ref. x-15017
CR20220371A (es) Agonistas heterocíclicos de glp-1
BR112021018822A2 (pt) Derivados de n-[1-(5-bromo-2-pirimidin-2-il-1,2,4-triazol-3-il)etil]-2-ciclopropil-6-(trifluorometil)piridina-4-carboxamida e compostos relacionados como inseticidas
AR046779A1 (es) Derivados de pirazol, metodos para su preparacion y usos de los mismos en la fabricacion de composiciones farmaceuticas y medicamentos que los contienen con actividad inhibitoria de trk para el tratamiento o profilaxis del cancer.
MX2023001311A (es) Agonistas heterociclicos de glp-1.
DK0620216T3 (da) Benzamidderivater og deres anvendelse som vasopressinantagonister
PE20031037A1 (es) Derivados de nicotinamida y una sal de tiotropio en combinacion para el tratamiento de enfermedades
AR054183A1 (es) Derivados de piridincarboxamida y su uso como agentes anticancerigenos. procesos de obtencion y composiciones farmaceuticas.
DE60230127D1 (de) Inhibitoren von integrin alpha-v-beta-6
DK0681581T3 (da) Substituerede, kondenserede, pyrazolforbindelser og deres anvendelse som herbicider.
AR045037A1 (es) Tetrahidro-1h-pirazolo [3,4-c] piridinas sustituidas, composiciones que las contienen y su utilizacion.
DK0765314T3 (da) Benzoheterocykliske derivater, der kan anvendes som vasopressin- eller oxytocinmodulatorer
AR041672A1 (es) Compuesto biciclico de benzamida, composicion farmaceutica que lo comprende, su uso para la fabricacion de un medicamento y procedimiento para prepararlo
EA200300919A1 (ru) N-замещенные неарильные гетероциклические антагонисты nmda/nr2b
AR064197A1 (es) Derivados de pirimidina y piridina inhibidores de la proteina quinasa
ATE188962T1 (de) Herbizide
AR051202A1 (es) Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
BR0116571A (pt) Compostos heterocìclicos tendo atividade antibacteriana, processo para sua preparação e composições farmacêuticas contendo os mesmos
EA201070889A1 (ru) Замещённые гетероариламидные производные оксазепинопиримидона
ES2333802T3 (es) Inhibidores no nucleicos de transcriptasa inversa.
NO20072753L (no) 3-Etylidenhydrazinosubstituerte heterocykliske forbindelser som trombopoietinreseptoraktivatorer
EA201070891A1 (ru) Замещенные гетероариламидные производные диазепинопиримидона
EA200501226A1 (ru) Новая кристаллическая модификация негидратированного боскалида
PE20070124A1 (es) Derivados de heteroaril para tratar virus
AR124167A1 (es) Una nueva composición agroquímica que comprende compuestos de fenilamidina 3-sustituidos